Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM
Coming off its successful launch of Spinraza, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), Biogen Inc …
After Incyte Corporation (NASDAQ:INCY) announced positive clinical pipeline updates that had investors celebrating and shares soaring 9%, top analyst Eric Schmidt at Cowen …
In a research report released today, Cowen analyst Eric Schmidt reiterated a Market Perform rating on shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), after …
Celgene Corporation (NASDAQ:CELG) presented at JPM this morning, providing guidance updates and top-line FY2016 results. While FY2016 top-line results were slightly below expectations, …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares were initially up 6% this morning after the biotech firm and its wholly-owned subsidiary Akcea Therapeutics signed an …
Biogen Inc (NASDAQ:BIIB) has decided to promote from within, opting to transition Chief Commercial Officer Michel Vounatsos into the role of CEO, a …
Loxo Oncology Inc (NASDAQ:LOXO) gave investors cause to celebrate today, to the tune of shares rocketing 26%, after providing an encouraging regulatory update …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its third-quarter report today as well as offered a clinical update. In reaction, Cowen analyst Eric Schmidt notes …
As Exelixis, Inc.’s (NASDAQ:EXEL) “impressive launch continues” for its pipeline drug Cabometyx, approved to treat second-line advanced renal cell carcinoma (RCC), the most …
